Brief: Investment Company 3i Reports Passive Stake Of 9.9% In Transcode Therapeutics
26/07/2024 23:30
July 26 (Reuters) -
3i:
* 3I, LP REPORTS PASSIVE STAKE OF 9.9% IN TRANSCODE
THERAPEUTICS,
INC. AS OF JULY 23, 2024- SEC FILING
Source text for Eikon: ID:n0001753926-24-001271
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors